89bio, Inc. (ETNB)
- Previous Close
8.61 - Open
8.62 - Bid --
- Ask --
- Day's Range
8.20 - 8.71 - 52 Week Range
6.57 - 16.63 - Volume
511,372 - Avg. Volume
581,307 - Market Cap (intraday)
869.521M - Beta (5Y Monthly) 0.99
- PE Ratio (TTM)
-- - EPS (TTM)
-1.96 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.63
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
www.89bio.comRecent News: ETNB
View More
Performance Overview: ETNB
Trailing total returns as of 10/17/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ETNB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ETNB
View MoreValuation Measures
Market Cap
911.89M
Enterprise Value
407.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.77
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.25%
Return on Equity (ttm)
-36.50%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-174.61M
Diluted EPS (ttm)
-1.96
Balance Sheet and Cash Flow
Total Cash (mrq)
531.38M
Total Debt/Equity (mrq)
5.31%
Levered Free Cash Flow (ttm)
-126.63M
Research Analysis: ETNB
View MoreCompany Insights: ETNB
ETNB does not have Company Insights